Interim data from a Phase I/II clinical trial suggest that mRNA-3927, an investigational mRNA therapy from
A 70 percent reduction in the risk of metabolic decompensation events was reported by eight participants in the 12-month pretreatment period, according to the trial results published in Nature.
“We are excited to share the first published clinical data utilising an mRNA therapy for intracellular protein replacement,” stated Dr
A novel mRNA therapy
mRNA-3927 is a novel lipid nanoparticle (LNP)-encapsulated dual investigational mRNA therapy. By encoding for the PCC enzyme. it has potential to replace a missing or dysfunctional enzyme,
“Propionic acidaemia is a rare, inherited metabolic disorder that results from the body’s inability to process certain parts of proteins and lipids due to a specific enzyme deficiency. For people with [propionic acidaemia], harmful amounts of toxic metabolites can build up in the body and lead to metabolic decompensation events and multisystemic complications. These interim data indicate early signs of potential clinical benefit with mRNA-3927, and importantly also demonstrate that mRNA-3927 has infrequent treatment-limiting side effects. I am particularly proud of these results given that there are currently no therapeutic treatments approved for patients with this disease,"
Moderna announces first patient dosed in mRNA-3705 study
The company's ongoing global Phase I/II clinical trial assessed the safety, pharmacodynamics, and pharmacokinetics of the IV-administered treatment in participants aged one year and over. Study data was presented at the 2023
As of the latest data cut off at the end of
Last week,
The post mRNA therapy could provide intracellular protein replacement for rare disease appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source